Contravisory Investment Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $196K | Sell |
777
-2,217
| -74% | -$477K | 0.03% | 215 |
|
|
2026
Q1 | $651K | Sell |
2,994
-562
| -16% | -$125K | 0.13% | 124 |
|
|
2025
Q4 | $813K | Sell |
3,556
-313
| -8% | -$71.3K | 0.16% | 96 |
|
|
2025
Q3 | $896K | Sell |
3,869
-1,201
| -24% | -$245K | 0.17% | 82 |
|
|
2025
Q2 | $941K | Buy |
5,070
+160
| +3% | +$29.7K | 0.19% | 71 |
|
|
2025
Q1 | $1.03M | Buy |
4,910
+4,867
| +11,319% | +$946K | 0.22% | 55 |
|
|
2024
Q4 | $7.64K | Buy |
+43
| New | +$7.91K | ﹤0.01% | 325 |
|
|
2023
Q3 | – | Sell |
-2,576
| Closed | -$347K | – | 321 |
|
|
2023
Q2 | $347K | Sell |
2,576
-664
| -20% | -$97.4K | 0.09% | 156 |
|
|
2023
Q1 | $516K | Buy |
3,240
+27
| +0.8% | +$4.13K | 0.15% | 89 |
|
|
2022
Q4 | $519K | Buy |
3,213
+338
| +12% | +$51.8K | 0.14% | 85 |
|
|
2022
Q3 | $386K | Buy |
2,875
+114
| +4% | +$16.4K | 0.13% | 94 |
|
|
2022
Q2 | $423K | Buy |
2,761
+2,111
| +325% | +$323K | 0.14% | 87 |
|
|
2022
Q1 | $105K | Hold |
650
| – | – | 0.03% | 218 |
|
|
2021
Q4 | $88K | Hold |
650
| – | – | 0.02% | 220 |
|
|
2021
Q3 | $70K | Hold |
650
| – | – | 0.02% | 225 |
|
|
2021
Q2 | $73K | Hold |
650
| – | – | 0.02% | 216 |
|
|
2021
Q1 | $70K | Hold |
650
| – | – | 0.02% | 206 |
|
|
2020
Q4 | $70K | Sell |
650
-66,492
| -99% | -$6.39M | 0.02% | 196 |
|
|
2020
Q3 | $5.88M | Sell |
67,142
-753
| -1% | -$70.9K | 2% | 22 |
|
|
2020
Q2 | $6.52M | Buy |
67,895
+67,245
| +10,345% | +$5.92M | 2.4% | 7 |
|
|
2020
Q1 | $50K | Hold |
650
| – | – | 0.02% | 211 |
|
|
2019
Q4 | $58K | Hold |
650
| – | – | 0.02% | 220 |
|
|
2019
Q3 | $49K | Hold |
650
| – | – | 0.02% | 226 |
|
|
2019
Q2 | $47K | Hold |
650
| – | – | 0.02% | 226 |
|
|
2019
Q1 | $52K | Hold |
650
| – | – | 0.02% | 213 |
|
|
2018
Q4 | $60K | Hold |
650
| – | – | 0.03% | 182 |
|
|
2018
Q3 | $61K | Sell |
650
-91
| -12% | -$8.63K | 0.02% | 182 |
|
|
2018
Q2 | $69K | Hold |
741
| – | – | 0.03% | 206 |
|
|
2018
Q1 | $70K | Buy |
741
+84
| +13% | +$9.23K | 0.03% | 202 |
|
|
2017
Q4 | $64K | Buy |
657
+7
| +1% | +$660 | 0.02% | 198 |
|
|
2017
Q3 | $58K | Buy |
+650
| New | +$49.5K | 0.02% | 198 |
|
|
2015
Q4 | – | Sell |
-3,514
| Closed | -$191K | – | 206 |
|
|
2015
Q3 | $191K | Sell |
3,514
-411
| -10% | -$26.8K | 0.04% | 68 |
|
|
2015
Q2 | $264K | Hold |
3,925
| – | – | 0.06% | 58 |
|
|
2015
Q1 | $230K | Sell |
3,925
-400
| -9% | -$24.2K | 0.05% | 65 |
|
|
2014
Q4 | $283K | Sell |
4,325
-1,309
| -23% | -$82.5K | 0.06% | 52 |
|
|
2014
Q3 | $325K | Buy |
+5,634
| New | +$313K | 0.07% | 47 |
|
|
2013
Q3 | – | Sell |
-138,187
| Closed | -$5.71M | – | 121 |
|
|
2013
Q2 | $5.71M | Buy |
+138,187
| New | +$6.04M | 1.27% | 38 |
|
Other funds holding ABBV
Contravisory Investment Management's ABBV Position: Q2 2026 in Review
Contravisory Investment Management reduced its AbbVie (ABBV) stake by 74% in Q2 2026, selling an estimated $477K and leaving 777 shares worth $196K. The position accounts for 0.03% of the portfolio, ranked #215.
Contravisory Investment Management first reported a position in ABBV in Q2 2013 and has held it in 37 quarters since. The position peaked at $6.52M in Q2 2020. 4,206 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Contravisory Investment Management held 777 shares of AbbVie worth $196K as of Q2 2026.
- Contravisory Investment Management sold 2,217 AbbVie shares in Q2 2026, an estimated $477K.
- AbbVie made up 0.03% of Contravisory Investment Management's portfolio in Q2 2026, its #215 holding.
- Contravisory Investment Management first reported a position in AbbVie in Q2 2013 and has held it in 37 quarters since.
- Contravisory Investment Management's AbbVie position peaked at $6.52M in Q2 2020.
- 4,206 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Contravisory Investment Management's 13F filing for Q2 2026, filed 9 Jul 2026.